Literature DB >> 21640327

Dabigatran falsely elevates point of care international normalized ratio results.

Christina E DeRemer, Jaspal S Gujral, John W Thornton, Robert A Sorrentino.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21640327     DOI: 10.1016/j.amjmed.2011.02.009

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  6 in total

1.  Acute myocardial infarction after switching from warfarin to dabigatran.

Authors:  Wael Abuzeid; Hatim Al-Lawati; Neil Fam
Journal:  Oman Med J       Date:  2015-01

2.  [Pharmacology of the new oral anticoagulants].

Authors:  C-E Dempfle
Journal:  Herz       Date:  2012-06       Impact factor: 1.443

3.  Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.

Authors:  Jorge Ferreira; Daniel Ferreira; Miguel Viana-Baptista; Paulo Bettencourt; Rui Cernadas; Francisco Crespo
Journal:  Thrombosis       Date:  2012-05-07

Review 4.  Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.

Authors:  Alejandro Lazo-Langner; Eddy S Lang; James Douketis
Journal:  Crit Care       Date:  2013-06-17       Impact factor: 9.097

5.  ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention.

Authors:  Iolanda Enea; Loris Roncon; Michele Massimo Gulizia; Michele Azzarito; Cecilia Becattini; Amedeo Bongarzoni; Franco Casazza; Claudio Cuccia; Carlo D'Agostino; Matteo Rugolotto; Marco Vatrano; Eugenio Vinci; Paride Fenaroli; Dario Formigli; Paolo Silvestri; Federico Nardi; Maria Cristina Vedovati; Marino Scherillo
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

6.  Assessment of novel oral anticoagulant use within a community teaching hospital.

Authors:  Sultan Alghadeer; Lori Hornsby
Journal:  Saudi Pharm J       Date:  2016-02-15       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.